Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b Trial of Mavorixafor, an Oral CXCR4 Antagonist, in Combination With Ibrutinib in Patients With Waldenstrom's Macroglobulinemia (WM) Whose Tumors Express Mutations in MYD88 and CXCR4

NCT04274738 is registered in ClinicalTrials.gov with X4 Pharmaceuticals as lead sponsor.

NCT NCT04274738
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04274738 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b Trial of Mavorixafor, an Oral CXCR4 Antagonist, in Combination With Ibrutinib in Patients With Waldenstrom's Macroglobulinemia (WM) Whose Tumors Express Mutations in MYD88 and CXCR4
Lead sponsor
X4 Pharmaceuticals
Phase
Phase 1
Overall status
Completed
Start date
April 30, 2020
Completion date
October 31, 2022
Enrollment
16 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

waldenstrom's macroglobulinemia